Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 2c
Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.82), $0.02 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $19.2 million versus the consensus estimate of $14.8 million.
For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.